Our finding that the HPV E6/E7/IGF2BP2/m6A-MYC/glycolysis axis may play a key role in the pathogenesis of CC suggests that targeting HPV E6/E7 and downstream pathways may represent an attractive therapeutic option for the treatment of patients with this cancer. Here, MYC is linked to cancer.